The European Commission has approved, under the EU Merger Regulation, the proposed merger between the global pharmaceutical company Mylan and Upjohn, a business division of Pfizer, which operates Pfizer’s off-patent branded and generic established medicines. The decision is conditional on the divestment of Mylan’s business for certain generic medicines.
The transaction will lead to the combination of Mylan, one of the top five generic suppliers in the EEA with the originator Upjohn, whose products have lost exclusivity following patent expiries.
The Commission’s investigation found that no competition concerns arise for the majority of the products supplied by both Mylan and Upjohn...
Full text at GMPnews.Net